NLS Pharmaceutics AG (NLSPW)

CH — Healthcare Sector
Peers: RVPHW  GOVXW  ENTXW  NLSP  LIXTW 

Automate Your Wheel Strategy on NLSPW

With Tiblio's Option Bot, you can configure your own wheel strategy including NLSPW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NLSPW
  • Rev/Share 0.0
  • Book/Share -0.221
  • PB -10.0018
  • Debt/Equity -0.1849
  • CurrentRatio 0.1545
  • ROIC 0.4277

 

  • MktCap 7950784.0
  • FreeCF/Share -0.0365
  • PFCF -5.1868
  • PE -45.432
  • Debt/Assets 1.4358
  • DivYield 0
  • ROE 0.2254

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About NLS Pharmaceutics AG (NLSPW)

  • IPO Date 2021-01-29
  • Website https://nlspharma.com
  • Industry Biotechnology
  • CEO Mr. Alexander Zwyer M.B.A.
  • Employees None
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.